After a month-long pursuit, Auxilium Pharmaceuticals has succumbed to a sweetened US$2.6 B takeover bid from Endo International, dropping its plans for a tax inversion via a reverse merger with Canadian ophthalmology specialist QLT. The deal will strengthen Endo’s pharmaceutical business, adding complementary products in men’s health and urology, including Xiaflex® (collagenase clostridium histolyticum), Testim® (testosterone gel) and Testopel® (testosterone pellets). In September 2014, two FDA advisory panels voted in favour of restricting the usage of testosterone replacement therapies, however.